Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| parathyroid hormone analogues; peptides and glycopeptides | 5834 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Palopegteriparatide is a prodrug of parathyroid hormone (PTH[1-34]). Palopegteriparatide is designed to provide continuous exposure to PTH(1-34), which activates the PTH1 receptor.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 9, 2024 | FDA | Ascendis Pharma Bone | |
| Aug. 25, 2025 | PMDA | Teijin Pharma Limited |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | H05AA05 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS PARATHYROID HORMONES AND ANALOGUES Parathyroid hormones and analogues |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypoparathyroidism | indication | 36976004 | DOID:11199 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 8906847 | April 30, 2031 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 8906847 | April 30, 2031 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 8906847 | April 30, 2031 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 11590207 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 11857603 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12295989 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12453778 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 11590207 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 11857603 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12295989 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12453778 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 11590207 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 11857603 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12295989 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12453778 | Sept. 28, 2037 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12403182 | Nov. 12, 2042 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12403182 | Nov. 12, 2042 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12403182 | Nov. 12, 2042 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | Aug. 9, 2029 | NEW CHEMICAL ENTITY |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | Aug. 9, 2029 | NEW CHEMICAL ENTITY |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | Aug. 9, 2029 | NEW CHEMICAL ENTITY |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | Aug. 9, 2031 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | Aug. 9, 2031 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | YORVIPATH | ASCENDIS PHARMA BONE | N216490 | Aug. 9, 2024 | RX | SOLUTION | SUBCUTANEOUS | Aug. 9, 2031 | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS |
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Parathyroid hormone/parathyroid hormone-related peptide receptor | GPCR | Kd | 5.38 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2222514-07-8 | SECONDARY_CAS_RN |
| CHEMBL5095475 | ChEMBL_ID |
| C000731747 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4043376 | VANDF |
| C5557539 | UMLSCUI |
| CHEBI:759036 | CHEBI |
| 11060 | INN_ID |
| d10211 | MMSL |
| 13484 | IUPHAR_LIGAND_ID |
| G2N64C3385 | UNII |
| 2693635 | RXNORM |
| 43996711000001104 | SNOMEDCT_US |
| D12395 | KEGG_DRUG |
| 019831 | NDDF |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Yorvipath | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73362-100 | INJECTION, SOLUTION | 168 ug | SUBCUTANEOUS | NDA | 32 sections |
| Yorvipath | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73362-100 | INJECTION, SOLUTION | 168 ug | SUBCUTANEOUS | NDA | 32 sections |
| Yorvipath | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73362-101 | INJECTION, SOLUTION | 294 ug | SUBCUTANEOUS | NDA | 32 sections |
| Yorvipath | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73362-101 | INJECTION, SOLUTION | 294 ug | SUBCUTANEOUS | NDA | 32 sections |
| Yorvipath | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73362-102 | INJECTION, SOLUTION | 420 ug | SUBCUTANEOUS | NDA | 32 sections |
| Yorvipath | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73362-102 | INJECTION, SOLUTION | 420 ug | SUBCUTANEOUS | NDA | 32 sections |